Les recommandations nationales fran?aises de prise en charge du cancer du sein infiltrant

详细信息    查看全文

• 作者：S. Giard (12296)
  B. Cutuli (22296)
  M. Antoine (32296)
  B. Barreau (42296)
  S. Besnard (52296)
  J. Bonneterre (12296)
  M. Campone (62296)
  L. Ceugnard (12296)
  J. M. Classe (62296)
  M. Cohen (72296)
  N. Dohoullou (82296)
  A. Fourquet (92296)
  J. M. Guinebretière (102296)
  C. Hennequin (112296)
  M. Leblanc-Onfroy (62296)
  L. Levy (122296)
  V. Mazeau-Woynar (52296)
  M. A. Mouret Reynier (132296)
  C. Rousseau (62296)
  L. Verdoni (52296)
  
• 关键词：Recommandations ; cancer du sein ; bilan initial ; radiothérapie ; traitements systémiques ; Guidelines ; breast cancer ; initial staging ; radiotherapy ; systemic treatments
• 刊名：Oncologie
• 出版年：2013
• 出版时间：June 2013
• 年：2013
• 卷：15
• 期：6
• 页码：346-358
• 全文大小：362KB
• 参考文献：1. Abe H, Schmidt RA, Kulkarni K, Sennett CA, Mueller JS, Newstead GM. Axillary lymph nodes suspicious for breast cancer metastasis: sampling with US-guided 14-gauge core-needle biopsyclinical experience in 100 patients. Radiology 2009;250(1):41-9. CrossRef
  2. Ciatto S, Brancato B, Risso G, Ambrogetti D, Bulgaresi P, Maddau C et al. Accuracy of fine needle aspiration cytology (FNAC) of axillary lymph nodes as a triage test in breast cancer staging. Breast Cancer Research & Treatment 2007;103(1):85-1. CrossRef
  3. Duchesne N, Jaffey J, Florack P, Duchesne S. Redefining ultrasound appearance criteria of positive axillary lymph nodes. Canadian Association of Radiologists Journal 2005;56(5):289-96.
  4. Houssami N, Ciatto S, Turner RM, Cody HS, III, Macaskill P. Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla. Annals of Surgery 2011;254(2):243-51. CrossRef
  5. Jung J, Park H, Park J, Kim H. Accuracy of preoperative ultrasound and ultrasound-guided fine needle aspiration cytology for axillary staging in breast cancer. ANZ Journal of Surgery 2010;80(4):271-75. CrossRef
  6. Mathijssen IM, Strijdhorst H, Kiestra SK, Wereldsma JC. Added value of ultrasound in screening the clinically negative axilla in breast cancer. Journal of Surgical Oncology 2006;94(5):364-67. CrossRef
  7. Nori J, Vanzi E, Bazzocchi M, Bufalini FN, Distante V, Branconi F et al. Role of axillary ultrasound examination in the selection of breast cancer patients for sentinel node biopsy. American Journal of Surgery 2007;193(1):16-0. CrossRef
  8. Brennan ME, Houssami N. Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer. Breast 2011.
  9. Fuster D, Duch J, Paredes P, Velasco M, Mu?oz M, Santamarìa G et al. Preoperative staging of large primary breast cancer with [18F] fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. Journal of Clinical Oncology 2008;26(29):4746-751. CrossRef
  10. Gerber B, Seitz E, Muller H, Krause A, Reimer T, Kundt G et al. Perioperative screening for metastatic disease is not indicated in patients with primary breast cancer and no clinical signs of tumor spread. Breast Cancer Research & Treatment 2003;82(1):29-7. CrossRef
  11. Koizumi M, Yoshimoto M, Kasumi F, Ogata E. What do breast cancer patients benefit from staging bone scintigraphy? Japanese Journal of Clinical Oncology 2001;31(6):263-69. CrossRef
  12. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. European Journal of Nuclear Medicine & Molecular Imaging 2005;32(11):1253-258. CrossRef
  13. Segaert I, Mottaghy F, Ceyssens S, De WW, Stroobants S, Van OC et al. Additional value of PET-CT in staging of clinical stage IIB and III breast cancer. Breast Journal 2010;16(6):617-24. CrossRef
  14. Schneider C, Fehr MK, Steiner RA, Hagen D, Haller U, Fink D. Frequency and distribution pattern of distant metastases in breast cancer patients at the time of primary presentation. Archives of Gynecology & Obstetrics 2003;269(1):9-2. CrossRef
  15. Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. Journal of Clinical Oncology 2006;24(36):5658-663. CrossRef
  16. Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. European Journal of Cancer 2009;45(16):2792-798. CrossRef
  17. Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I et al. Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. Breast Cancer Research 2006;8(4):R36. CrossRef
  18. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006;107(4):696-04. CrossRef
  19. Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den BW, Barillot I et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. New England Journal of Medicine 2001;345(19):1378-387. CrossRef
  20. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den BW, Fourquet A et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. Journal of Clinical Oncology 2007;25(22):3259-265. CrossRef
  21. Collette S, Collette L, Budiharto T, Horiot JC, Poortmans PM, Struikmans H et al. Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882-boost versus no boost- European Journal of Cancer 2008;44(17):2587-599. CrossRef
  22. Jones HA, Antonini N, Hart AA, Peterse JL, Horiot JC, Collin F et al. Impact of pathological characteristics on local relapse after breastconserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. Journal of Clinical Oncology 2009;27(30):4939-947. CrossRef
  23. Murphy C, Anderson PR, Li T, Bleicher RJ, Sigurdson ER, Goldstein LJ et al. Impact of the radiation boost on outcomes after breast-conserving surgery and radiation. International Journal of Radiation Oncology, Biology, Physics 2011;81(1):69-6. CrossRef
  24. Polgar C, Fodor J, Orosz Z, Major T, Takacsi-Nagy Z, Mangel LC et al. Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I-II breast cancer first results of the randomized Budapest boost trial. Strahlentherapie Und Onkologie 2002;178(11):615-23. CrossRef
  25. Poortmans PM, Collette L, Horiot JC, Van den Bogaert WF, Fourquet A, Kuten A et al. Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. Radiotherapy & Oncology 2009;90(1):80-5. CrossRef
  26. Romestaing P, Lehingue Y, Carrie C, Coquard R, Montbarbon X, Ardiet JM et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. Journal of Clinical Oncology 1997;15(3):963-68.
  27. Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JH, Jager JJ et al. The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC-boost vs. no boost-trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiotherapy & Oncology 2000;55(3):219-32. CrossRef
  28. Werkhoven E, Hart G, Tinteren H, Elkhuizen P, Collette L, Poortmans P et al. Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial. Radiotherapy & Oncology 2011;100(1):101-07. CrossRef
  29. START Trialists-Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology 2008;9(4):331-41. CrossRef
  30. START Trialists-Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008;371(9618):1098-107. CrossRef
  31. Cutuli B, De Lafontan B, Vitali E, Costa L, Aristei C, Marchal C et al. Breast conserving treatment (BCT) for stage I–II breast cancer in elderly women: analysis of 927 cases. Critical Reviews in Oncology Hematology 2009;71(1):79-8. CrossRef
  32. Hopwood P, Haviland JS, Sumo G, Mills J, Bliss JM, Yarnold JR et al. Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncology 2010;11(3):231-40. CrossRef
  33. James ML, Lehman M, Hider PN, Jeffery M, Francis DP, Hickey BE. Fraction size in radiation treatment for breast conservation in early breast cancer. Cochrane Database of Systematic Reviews 2008;(3):CD003860.
  34. Kirova YM, Campana F, Savignoni A, Laki F, Muresan M, Dendale R et al. Breast-conserving treatment in the elderly: long-term results of adjuvant hypofractionated and normofractionated radiotherapy. International Journal of Radiation Oncology, Biology, Physics 2009;75(1):76-1. CrossRef
  35. Ortholan C, Hannoun-Levi JM, Ferrero JM, Largillier R, Courdi A. Longterm results of adjuvant hypofractionated radiotherapy for breast cancer in elderly patients. International Journal of Radiation Oncology, Biology, Physics 2005;61(1):154-62. CrossRef
  36. Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncology 2006;7(6):467-71. CrossRef
  37. Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiotherapy & Oncology 2005;75(1):9-7. CrossRef
  38. Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. Journal of the National Cancer Institute 2002;94(15):1143-150. CrossRef
  39. Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S et al. Long-term results of hypofractionated radiation therapy for breast cancer. New England Journal of Medicine 2010;362(6):513-20. CrossRef
  40. Dodwell DJ, Dyker K, Brown J, Hawkins K, Cohen D, Stead M et al. A randomised study of whole-breast vs tumour-bed irradiation after local excision and axillary dissection for early breast cancer. Clinical Oncology (Royal College of Radiologists) 2005;17(8):618-22. CrossRef
  41. Polgar C, Fodor J, Major T, Nemeth G, Lovey K, Orosz Z et al. Breastconserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma--year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics 2007;69(3):694-02. CrossRef
  42. Polgar C, Van LE, Potter R, Kovacs G, Polo A, Lyczek J, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol 2010; 94: 264-73. CrossRef
  43. Ribeiro GG, Magee B, Swindell R, Harris M, Banerjee SS. The Christie Hospital breast conservation trial: an update at 8 years from inception. Clinical Oncology (Royal College of Radiologists) 1993;5(5):278-83. CrossRef
  44. Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 2009; 74: 987-001. CrossRef
  45. Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 2010;376(9735):91-02. CrossRef
  46. Chen RC, Lin NU, Golshan M, Harris JR, Bellon JR. Internal mammary nodes in breast cancer: diagnosis and implications for patient management -a systematic review. Journal of Clinical Oncology 2008;26(30):4981-989. CrossRef
  47. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366(9503):2087-106.
  48. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncology 2005;6(8):557-65. CrossRef
  49. Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. Journal of the National Cancer Institute 2005;97(6):419-24. CrossRef
  50. Harris EE, Correa C, Hwang WT, Liao J, Litt HI, Ferrari VA et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. Journal of Clinical Oncology 2006;24(25):4100-106. CrossRef
  51. Hojris I, Overgaard M, Christensen JJ, Overgaard J. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet 1999;354(9188):1425-430.
  52. Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. Journal of the National Cancer Institute 2007;99(5):365-75. CrossRef
  53. Huang O, Wang L, Shen K, Lin H, Hu Z, Liu G et al. Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis: analysis of 2,269 Chinese breast cancer patients treated with extended radical mastectomy. Breast Cancer Research & Treatment 2008;107(3):379-87. CrossRef
  54. Lacour J, Le M, Caceres E, Koszarowski T, Veronesi U, Hill C. Radical mastectomy versus radical mastectomy plus internal mammary dissection. Ten year results of an international cooperative trial in breast cancer. Cancer 1983;51(10):1941-943.
  55. McGale P, Darby SC, Hall P, Adolfsson J, Bengtsson NO, Bennet AM et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiotherapy & Oncology 2011;100(2):167-75. CrossRef
  56. Matzinger O, Heimsoth I, Poortmans P, Collette L, Struikmans H, Vean den BW et al. Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925). Acta Oncologica 2010;49(1):24-4. CrossRef
  57. Patt DA, Goodwin JS, Kuo YF, Freeman JL, Zhang DD, Buchholz TA et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. Journal of Clinical Oncology 2005;23(30):7475-482. CrossRef
  58. Veronesi U, Cascinelli N, Greco M, Bufalino R, Morabito A, Galluzzo D et al. Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Annals of Surgery 1985;202(6):702-07. CrossRef
  59. Veronesi U, Arnone P, Veronesi P, Galimberti V, Luini A, Rotmensz N et al. The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series. Annals of Oncology 2008;19(9):1553-560. CrossRef
  60. Daveau C, Stevens D, Brain E, Berges O, Villette S, Moisson P et al. Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy? International Journal of Radiation Oncology, Biology, Physics 2010;78(2):337-42. CrossRef
  61. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Buzdar AU et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. Journal of Clinical Oncology 2004;22(23):4691-699. CrossRef
  62. Le Scodan R, Selz J, Stevens D, Bollet MA, de la Lande B, Daveau C et al. Radiotherapy for Stage II and Stage III Breast Cancer Patients with Negative Lymph Nodes After Preoperative Chemotherapy and Mastectomy. International Journal of Radiation Oncology, Biology, Physics 2011.
  63. McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. International Journal of Radiation Oncology, Biology, Physics 2007;68(4):1004-009. CrossRef
  64. Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM et al.Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. Journal of Clinical Oncology 2008;26(35):5697-704. CrossRef
  65. Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. Journal of Clinical Oncology 2009;27(34):5693-699. CrossRef
  66. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. Journal of Clinical Oncology 2009;27(34):5700-706. CrossRef
  67. Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clinical Cancer Research 2003;9(3):923-30.
  68. Park YH, Kim ST, Cho EY, Choi YL, Ok ON, Baek HJ et al. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Breast Cancer Research & Treatment 2010;119(3):653-61. CrossRef
  69. Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT. The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Research & Treatment 1994;32(3):281-90. CrossRef
  70. Blamey RW, Ellis IO, Pinder SE, Lee AH, Macmillan RD, Morgan DA et al. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-999. Eur J Cancer 2007;43(10):1548-555. CrossRef
  71. Campbell HE, Taylor MA, Harris AL, Gray AM. An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. British Journal of Cancer 2009;101(7):1074-084. CrossRef
  72. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Research & Treatment 1992;22(3):207-19. CrossRef
  73. Mook S, Schmidt MK, Rutgers EJ, van d V, Visser O, Rutgers SM et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncology 2009;10(11):1070-076. CrossRef
  74. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. Journal of Clinical Oncology 2005;23(12):2716-725. CrossRef
  75. Ozanne EM, Braithwaite D, Sepucha K, Moore D, Esserman L, Belkora J. Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model. Journal of Clinical Oncology 2009;27(2):214-19. CrossRef
  76. Paridaens RJ, Gelber S, Cole BF, Gelber RD, Thurlimann B, Price KN et al. Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Research & Treatment 2010;123(1):303-10. CrossRef
  77. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. Journal of Clinical Oncology 2001;19(4):980-91.
  78. Van Belle V, Van Calster B, Brouckaert O, Vanden Bempt I, Pintens S, Harvey V et al. Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis. Journal of Clinical Oncology 2010;28(27):4129-134. CrossRef
  79. Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. Journal of Clinical Oncology 2000;18(3):584-90.
  80. Cold S, During M, Ewertz M, Knoop A, Moller S. Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). British Journal of Cancer 2005;93(6):627-32. CrossRef
  81. Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI. Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Research & Treatment 2006;99(3):313-21. CrossRef
  82. Jara Sanchez C, Ruiz A, Martin M, Anton A, Munarriz B, Plazaola A et al. Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM). Breast Cancer Research & Treatment 2007;101(2):215-23. CrossRef
  83. Lohrisch C, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. Journal of Clinical Oncology 2006;24(30):4888-894. CrossRef
  84. Shannon C, Ashley S, Smith IE. Does timing of adjuvant chemotherapy for early breast cancer influence survival? Journal of Clinical Oncology 2003;21(20):3792-797. CrossRef
  
• 作者单位：S. Giard (12296)
  B. Cutuli (22296)
  M. Antoine (32296)
  B. Barreau (42296)
  S. Besnard (52296)
  J. Bonneterre (12296)
  M. Campone (62296)
  L. Ceugnard (12296)
  J. M. Classe (62296)
  M. Cohen (72296)
  N. Dohoullou (82296)
  A. Fourquet (92296)
  J. M. Guinebretière (102296)
  C. Hennequin (112296)
  M. Leblanc-Onfroy (62296)
  L. Levy (122296)
  V. Mazeau-Woynar (52296)
  M. A. Mouret Reynier (132296)
  C. Rousseau (62296)
  L. Verdoni (52296)
  
  12296. Centre Oscar Lambret, 3 rue Frédéric Combemale, 59020, Lille cedex, France
  22296. Institut du cancer Courlancy, 38 Rue de Courlancy, 51000, Reims, France
  32296. AP-HP H?pital Tenon, 4, rue de la Chine, 75970, Paris cedex 20, France
  42296. 62 avenue de Bayonne, 64600, Anglet, France
  52296. Département recommandations et bon usage du médicament -Direction des recommandations et de la qualité de l’expertise, Institut national du cancer, 52 avenue André Morizet, 92513, Boulogne-Billancourt Cedex, France
  62296. Centre René Gauducheau (Saint-Herblain) Site hospitalier Nord, boulevard Jacques Monod, 44805, Saint-Herblain Cedex, France
  72296. Institut Paoli Calmettes, Bd de Sainte Marguerite, 13009, Marseille, France
  82296. Polyclinique Bordeaux Nord Aquitaine, 15 à 33, rue Claude Boucher, 33077, Bordeaux cedex, France
  92296. Institut Curie, 26 rue d’Ulm, 75005, Paris, France
  102296. H?pital René Huguenin/Institut Curie, 35, rue Dailly, 92210, Saint-Cloud, France
  112296. H?pital Saint-Louis, 1, Avenue Claude-Vellefaux, 75010, Paris, France
  122296. Institut de radiologie de Paris, 31 Avenue Hoche, 75008, Paris, France
  132296. Centre Jean Perrin, 58, rue Montalembert, B.P. 392, 63011, Clermont-Ferrand, France
  

文摘

The French National Cancer Institute (INCa) and Société fran?aise de sénologie et pathologie mammaire (SFSPM), in collaboration with a multidisciplinary experts group, have published the French national clinical practice guidelines on a selection of 11 currently debated questions regarding the management of non metastatic invasive breast cancer. Those guidelines are based on a comprehensive analysis of the current published evidence dealing with those issues, secondly reviewed by 100 French reviewers.